An extensive data review of the cholesterol drug Vytorin turned up no evidence that the drug causes cancer, federal drug regulators say.
Following up on concerns raised by a patient study last year, the Food and Drug Administration examined all of the data from that study and reviewed available information from two ongoing large studies, the Associated Press reported.
But whether Vytorin, which is made by Merck & Co., is linked to a higher risk of cancer or death from cancer cannot definitively be ruled out, the FDA said.
Vytorin combines two types of cholesterol pills, Zetia and Zocor.